Literature DB >> 15632040

Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.

Morand Piert1, Hans-Jürgen Machulla, Maria Picchio, Gerald Reischl, Sybille Ziegler, Piyush Kumar, Hans-Jürgen Wester, Roswitha Beck, Alexander J B McEwan, Leonard I Wiebe, Markus Schwaiger.   

Abstract

UNLABELLED: The study was performed to compare the (18)F-labeled nitroimidazole compound fluoroazomycin arabinoside ((18)F-FAZA) with the standard hypoxia tracer fluoromisonidazole ((18)F-FMISO) in detection of tumor tissue hypoxia and to verify the oxygenation dependency of (18)F-FAZA uptake.
METHODS: Biodistribution of (18)F-FAZA was studied at various time points in EMT6 tumor-bearing BALB/c mice and in AR42J and A431 tumor-bearing nude mice and compared with that of (18)F-FMISO. The presence of tumor tissue hypoxia was verified in 5 EMT6 and 5 AR42J tumors using an oxygen-sensing needle electrode system. To evaluate the oxygenation dependency of (18)F-FAZA uptake, using the Munich prototype animal PET scanner, 2 serial PET scans were performed in 13 A431 tumor-bearing nude mice breathing pure oxygen or room air on 1 d and then selecting the other oxygen breathing condition on the following day. In addition, digital autoradiography was performed with EMT6 tumor-bearing (18)F-FAZA-dosed, nude mice breathing either room air (n = 8) or carbogen (n = 9).
RESULTS: Tissue partial pressure of oxygen (Po(2)) electrode measurements revealed that tumor hypoxia was present under room air breathing in EMT6 (tissue Po(2) = 2.9 +/- 2.6) and AR42J tumors (tissue Po(2) = 0.4 +/- 0.2), which was significantly lower compared with that of reference tissue (tissue Po(2) = 25.8 +/- 6.7 and tissue Po(2) = 29.0 +/- 3.0 [mean +/- SD], respectively; P < 0.01). In all tumor models, (18)F-FAZA displayed significantly higher tumor-to-muscle and tumor-to-blood ratios compared with (18)F-FMISO, indicating a faster clearance of (18)F-FAZA from normal tissues. In AR42J tumors, (18)F-FAZA tumor-to-normal ratios were found to increase over time. Serial animal (18)F-FAZA PET studies showed that the tumor-to-background ratio was significantly higher in animals breathing room air compared with that of animals breathing pure oxygen (7.3 +/- 2.3 vs. 4.2 +/- 1.2, respectively; P < 0.001). Similarly, autoradiography showed significantly higher tumor-to-muscle ratios in mice breathing room air compared with those of animals breathing carbogen (5.3 +/- 0.8 vs. 2.2 +/- 0.8; respectively; P < 0.02).
CONCLUSION: (18)F-FAZA shows superior biokinetics and is, thus, a promising PET tracer for the visualization of tumor hypoxia. This study also verified a hypoxia-specific uptake mechanism for (18)F-FAZA in murine tumor models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15632040

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  93 in total

1.  Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.

Authors:  Nilesh K Wagh; Zhengyuan Zhou; Sunny M Ogbomo; Wen Shi; Susan K Brusnahan; Jered C Garrison
Journal:  Bioconjug Chem       Date:  2012-02-16       Impact factor: 4.774

Review 2.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

3.  A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).

Authors:  Satish K Chitneni; Gerald T Bida; Mark W Dewhirst; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-06-22       Impact factor: 2.408

Review 4.  [Molecular imaging with new PET tracers].

Authors:  A J Beer; M Schwaiger
Journal:  Radiologe       Date:  2007-01       Impact factor: 0.635

5.  Imaging of tumour hypoxia using PET and 18F-labelled tracers: biology meets technology.

Authors:  Tove Grönroos; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

6.  PET imaging with hypoxia tracers: a must in radiation therapy.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04       Impact factor: 9.236

7.  GdDO3NI, a nitroimidazole-based T1 MRI contrast agent for imaging tumor hypoxia in vivo.

Authors:  Praveen K Gulaka; Federico Rojas-Quijano; Zoltan Kovacs; Ralph P Mason; A Dean Sherry; Vikram D Kodibagkar
Journal:  J Biol Inorg Chem       Date:  2013-11-27       Impact factor: 3.358

Review 8.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Phosphorescent oxygen sensor with dendritic protection and two-photon absorbing antenna.

Authors:  Raymond P Briñas; Thomas Troxler; Robin M Hochstrasser; Sergei A Vinogradov
Journal:  J Am Chem Soc       Date:  2005-08-24       Impact factor: 15.419

10.  Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome.

Authors:  Edward E Graves; Rodney J Hicks; David Binns; Mathias Bressel; Quynh-Thu Le; Lester Peters; Richard J Young; Danny Rischin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.